RBC says Edgewise abstract leak ‘appears legitimate,’ supportive of ‘7500

RBC Capital notes that one of Edgewise Therapeutics’ abstracts for their HCM drug EDG-7500 was leaked ahead of the presentations on September 28 and 29 at the HFSA Annual Scientific Meeting, and while the firm cannot confirm its authenticity, it “appears to be legitimate.” The purported abstract release supports the potential for EDG-7500’s profile to be superior to that of CMIs, and while the amount of data in the abstract was limited, it “does take the worst case scenario off the table,” according to the analyst, who continues to believe that ‘7500 can show impressive efficacy and would be buyers into the full data. RBC has an Outperform rating and $32 price target on Edgewise shares.